Targeting Class I Histone Deacetylases in a "Complex" Environment

Area of Science:

• Biochemistry
• Pharmacology
• Molecular Biology

Background:

• Histone deacetylase (HDAC) inhibitors are established anticancer agents with therapeutic potential for HIV, Alzheimer's disease, and Friedreich's ataxia.
• Current HDAC inhibitors lack specificity, targeting multiple deacetylases due to similar active site structures, posing a challenge for drug design.
• HDACs 1, 2, and 3 are components of distinct multi-subunit complexes with specific biological roles.

Purpose of the Study:

• To review structural information on HDAC complexes.
• To discuss strategies for developing isoform-selective HDAC inhibitors by targeting these complexes.
• To explore potential therapeutic applications of targeted HDAC inhibition.

Main Methods:

• Literature review of structural and functional data on HDAC complex assembly.
• Analysis of structural similarities and differences in HDAC active sites.
• Discussion of potential targeting strategies for specific HDAC complexes.

Main Results:

• HDACs 1, 2, and 3 participate in distinct multi-subunit complexes.
• Structural and functional data on complex assembly offer opportunities for targeted inhibition.
• Targeting complexes presents a viable strategy to achieve isoform selectivity.

Conclusions:

• Targeting multi-subunit HDAC complexes offers a promising approach to enhance inhibitor selectivity.
• Understanding complex assembly is crucial for designing novel HDAC-targeted therapeutics.
• This strategy could lead to more effective treatments for cancer and other HDAC-related diseases.